JWCTF (JW (Cayman) Therapeutics Co) Total Liabilities : $68.63 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co Total Liabilities?

JW (Cayman) Therapeutics Co's Total Liabilities for the quarter that ended in Jun. 2024 was $68.63 Mil.

JW (Cayman) Therapeutics Co's quarterly Total Liabilities declined from Jun. 2023 ($71.49 Mil) to Dec. 2023 ($64.74 Mil) but then increased from Dec. 2023 ($64.74 Mil) to Jun. 2024 ($68.63 Mil).

JW (Cayman) Therapeutics Co's annual Total Liabilities increased from Dec. 2021 ($51.14 Mil) to Dec. 2022 ($62.69 Mil) and increased from Dec. 2022 ($62.69 Mil) to Dec. 2023 ($64.74 Mil).

JW (Cayman) Therapeutics Co Total Liabilities Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Total Liabilities Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

53.49

51.14

62.69

64.74

70.21

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial								62.69	71.49	64.74	68.63	70.21

JW (Cayman) Therapeutics Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

JW (Cayman) Therapeutics Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	37.039	+	(27.701	+	-7.105427357601E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	64.74

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	300.565	-	235.825
	=	64.74

JW (Cayman) Therapeutics Co's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	44.582	+	(24.047	+	-0.0010000000000012
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	68.63

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	272.902	-	204.274
	=	68.63

JW (Cayman) Therapeutics Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

02126:Hong Kong JNY:Germany

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co Headlines

No Headlines